TB-500 dosage starts with “of what?”

The human amounts were intravenous thymosin beta-4

Searching for TB-500 dosage turns up numbers from the Phase 1 study of full-length synthetic thymosin beta-4. Forty healthy volunteers, in four cohorts of ten, received 42, 140, 420 or 1260 mg intravenously, as a single dose and then daily for 14 days. The study reported only infrequent mild or moderate adverse events, no dose-limiting toxicities and no serious adverse events.

Those are exposures measured in a study; copying them for personal use goes beyond its findings. The participants were healthy volunteers in a safety and pharmacokinetic trial; the substance was the whole protein. Calling those trial amounts instructions for the seven-residue fragment asks the paper to answer a question it never tested. That substitution loses me.

The animal studies do not converge on a recipe

In rats with embolic stroke, intraperitoneal full-length thymosin beta-4 at 2 and 12 mg/kg improved neurological function, while 18 mg/kg gave no significant benefit. In dystrophin-deficient mice, 150 µg given intraperitoneally twice weekly for six months increased regenerating fibres without significant gains in strength or systolic cardiac function.

Both studies gave a precisely stated substance in a particular disease model. They did not discover interchangeable doses of a general recovery medicine. I put the unsuccessful outcomes beside the administered amounts because the amount alone says remarkably little.

The 2026 sports-medicine review describes scarce human safety data for unapproved repair peptides. Community loading and maintenance practices have no controlled human-trial validation; this page provides no human schedule.

TB-500 half-life: the missing entry

No validated human pharmacokinetic half-life exists for the TB-500 heptapeptide in the evidence covered here. The intravenous full-length protein study reported dose-proportional pharmacokinetics and a half-life that increased with dose. Those observations cannot supply a clearance time for another molecule administered another way.

The equine anti-doping analysis detected TB-500 and its metabolites in plasma and urine. Detecting a substance is a different task from measuring its half-life in people. I see no defensible human dosing interval hidden in that detection work. The legal-status page covers the sport implications.

A stated amount still needs an identified substance

There is an additional problem before any comparison of amounts: the identity and purity of unregulated research material. The analytical paper on misbranded and adulterated preparations makes the distinction clear: a label leaves chemical identity unverified.

Anecdotal reports cannot repair that uncertainty. If the material, other interventions and outcome are not controlled, an account of recovery cannot establish which molecule caused it. The community-report page preserves the experiences as anecdotes, without turning them into a regimen.